Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
Completed
Conditions studied: Metastatic Breast Cancer
In brief
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Key facts
- Study ID
- NCT07008963
- Run by
- AstraZeneca
- People needed
- 48
- Starts
- 2025-07-31
- Expected to finish
- 2025-11-28
- Last updated by the study team
- 2026-02-23
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Redwood Shores, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.